
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Vervain leaf (Verbena officinalis) contains iridoid glycosides like verbenalin and flavonoids that provide antioxidant activity with demonstrated phosphomolybdenum-reducing activity of 3.62 mmol TE/g. The leaf's bioactive compounds inhibit acetylcholinesterase (5.13 mg GALAE/g) and reduce inflammation by up to 61% through phenolic and verbascoside-mediated pathways.

Reported Benefits (Provisional)
Origin & History

Vervain (Verbena officinalis) is a perennial herbaceous plant native to temperate regions across Europe, North Africa, and Western Asia. Historically revered for its medicinal properties, it is valued in functional nutrition for its adaptogenic and nervine qualities.
Research Narrative (Provisional)
Emerging scientific studies, including in vitro and animal models, indicate Vervain's potential for anxiolytic, anti-inflammatory, and hepatoprotective effects, attributed to its iridoid glycosides and flavonoids. Further human clinical trials are necessary to confirm these benefits and establish optimal therapeutic applications.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Minerals: Iron, Calcium, Magnesium - Phytochemicals: Iridoid glycosides (verbenalin, hastatoside), Flavonoids (luteolin, apigenin), Alkaloids, Bitter compounds, Polysaccharides, Tannins
Reported Mechanism (Provisional)
Vervain leaf's iridoid glycosides (verbenalin, aucubin) and flavonoids (luteolin glucuronides) scavenge free radicals and inhibit xanthine oxidase with IC50 values of 12.77-18.05 µg/mL. Verbascoside and phenolic compounds like dicaffeoylquinic acids reduce inflammation and modulate NK cell activation. The neuroprotective effects involve reducing β-amyloid toxicity and PKR/JNK phosphorylation in cortical neurons.
Clinical Narrative (Provisional)
Evidence for vervain leaf comes primarily from in vitro and animal studies, with no published randomized controlled trials in humans. Anti-inflammatory studies show methanolic extracts reduced inflammation by 38% while supercritical CO2 extracts achieved 61% reduction in animal models. Enzyme inhibition studies demonstrate acetylcholinesterase inhibition at 5.13 mg GALAE/g and tyrosinase inhibition at 102.33 mg KAE/g in laboratory assays. Human clinical trials are necessary to establish therapeutic efficacy and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







